Brand versus compounded, on price: the spread is not what you were told
Compounded is usually cheaper, and that's most of why the compounded market exists. It isn't reliably cheaper. Reading 531 compounded and 71 brand GLP-1 prices off sellers' own pages, 17 brand lines sit at or below the middle of the compounded range — and the dearest compounded line on this roster costs more than most of the brand ones.
What this comes down to
- Compounded GLP-1 prices here run $54 to $947 a month with a middle of $199. Brand runs $25 to $1899 with a middle of $399.
- Seventeen of the 71 brand lines we have read sit at or below the middle of the compounded range. The two markets overlap.
- The brand range is bimodal: manufacturer direct-pay pricing sits at one end and retail brand pricing through a telehealth platform sits at the other, and they are not the same product experience.
- Whatever the spread, the compounded product was never reviewed by the FDA for safety, effectiveness or quality before sale, and no randomized trial has compared a compounded version with the approved one.
The two ranges, side by side
| Compounded | Brand | |
|---|---|---|
| Prices read | 531 | 71 |
| Sellers | 160 | 26 |
| Lowest | $54 | $25 |
| Lower quartile | $149 | $268.68 |
| Middle | $199 | $399 |
| Upper quartile | $269 | $1299 |
| Highest | $947 | $1899 |
Every GLP-1 medication price on our roster, split by form. Each figure was read off the seller's own page.
Read the quartiles rather than the extremes and the shape is clear. The compounded market is tight: half of it lives between $149 and $269. The brand market is not a market at all so much as two of them, with a lower quartile of $268.68 and an upper quartile of $1299[1]. There is no single brand price to compare against.
Why the brand range has two ends
Because two different things are being sold. At the low end, a manufacturer sells directly to cash-paying patients at a published, dose-tiered price. At the high end, a telehealth platform dispenses the same branded product and prices it closer to what a pharmacy counter charges without insurance. Both are the brand. Neither is a compounded drug. The gap between them is distribution.
On our roster the direct-pay end is represented by LillyDirect and NovoCare Pharmacy, whose lines are priced by dose rather than by plan length. 19 of the 23 brand rungs inside a multi-price group on this roster name a milligram figure in the seller's own label, and 0 name a plan term.
Those milligrams aren't optional. The approved label steps from a 2.5 mg starting dose, which it says is not approved as a maintenance dosage, up to 5, 10 or 15 mg[5]. What that ladder costs as the dose climbs is its own question, and a large one.
A compounded monthly figure that assumes a prepaid year, set beside a brand figure with no term attached. One is a commitment and the other is a price. Every table in this market does it, ours included unless you read the terms column, which is why every rung we publish keeps the seller's own wording intact.
The rule that decides whether the cheap tier can exist at all
Federal law lets a compounder prepare a version of a drug that is on the FDA's shortage list, under conditions[2]. That was the door most compounded GLP-1s came through and it has closed. We read the agency's shortage database directly on the day this page was updated[3]: 74 entries, 70 of them currently in shortage. Liraglutide injection is among them. Semaglutide injection and tirzepatide injection are not.
So the price gap now has to justify itself against a different rule — the one about compounded products that are essentially copies of an available drug — rather than against a supply emergency. What compounded actually means, legally walks that whole analysis, and the FDA's guidance on it is explicit that a lower price is not by itself sufficient to establish that a compounded product is not essentially a copy.
What the price difference does not tell you
PubMed, via the E-utilities API
compounded[tiab] AND (semaglutide[tiab] OR tirzepatide[tiab]) AND "randomized controlled trial"[pt] AND "humans"[mh]
Returned 0. Positive control — semaglutide, identical trial filter — returned 306 through the identical filter in the same session.
The control is the same molecule through the same filter, and it finds 306 trials. What does not exist is a randomized trial of a compounded preparation — against the brand or against anything else. The saving is measurable; the equivalence is not.
The agency's own position is that compounded drugs are not FDA approved and that it does not verify their safety, effectiveness or quality before they are marketed[2]. It also lists a company claiming that a compounded drug is the same as an FDA-approved drug first among its telehealth red flags[4]. A price comparison is not a claim of equivalence, and a seller that turns one into the other has crossed a line the FDA has drawn in writing.
First: does the compounded figure assume a plan term, and does the brand figure? Second: which pharmacy compounds it, and is that a state-licensed pharmacy or a registered outsourcing facility? The second question has nothing to do with price and everything to do with what you are comparing.
Put a real seller's medication price and its recurring fee into the calculator over the months you expect to take it, and the brand-versus-compounded question usually answers itself for your particular case — which is the only case that matters. The full cash range is the wider view.
Questions people actually ask
Is compounded semaglutide always cheaper than Wegovy or Ozempic?
No. On our own roster, 17 of the 71 brand GLP-1 prices we have read sit at or below the middle of the compounded range, and the most expensive compounded line costs more than most brand lines. The ranges overlap in the middle.
Why is brand pricing so different from one seller to another?
Because two different channels are being compared. A manufacturer selling directly to cash-paying patients publishes a dose-tiered price; a telehealth platform dispensing the same branded product prices it closer to a retail pharmacy counter. Both figures are real and they are not comparable.
Is the compounded version the same drug?
It contains the same molecule. It is a different product, made by a different party, under rules that do not include FDA review for safety, effectiveness or quality before marketing. No randomized trial has compared a compounded preparation with the approved product.
Is semaglutide still on the FDA shortage list?
Not on the day we read the database. The current and resolved table held 74 entries, 70 marked currently in shortage, and neither semaglutide injection nor tirzepatide injection appeared. Liraglutide injection did, which is what makes the absence of the other two meaningful.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.The Telehealth Graded price record. Telehealth Graded, 2026. SourceEvery count, range and quartile comparing the brand and compounded markets in this article is computed at build time from the site's own price records, each read off the seller's own page and stamped with the day we read it.
- 2.Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025Compounded drugs are not FDA approved and the agency does not verify their safety, effectiveness or quality before marketing; federal law permits compounding a version of a drug on the FDA shortage list under stated conditions; and a lower price is not sufficient to establish that a compounded product is not essentially a copy of an available one.
- 3.FDA Drug Shortages: current and resolved drug shortages. U.S. Food and Drug Administration, accessdata, 2026. SourceThe rendered current-and-resolved index held 74 entries on the day it was read, 70 marked currently in shortage and four resolved. Liraglutide injection appeared as currently in shortage; tirzepatide returned no row at all and semaglutide appeared only as a tablet entry.
- 4.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026. Source · Document dated September 2026The FDA's telehealth red flags for consumers, the first of which is a company that claims a compounded drug is the same as an FDA-approved drug, and the second of which is a company offering medicine at deep discounts or prices that seem too good to be true.
- 5.ZEPBOUND (tirzepatide) injection — FDA prescribing information. U.S. Food and Drug Administration, Structured Product Labeling, 2026. Source · Document dated August 2026The approved brand product against which a compounded tirzepatide preparation is being priced: a starting dosage of 2.5 mg once weekly, maintenance dosages of 5, 10 or 15 mg, and a maximum of 15 mg once weekly.
Key figures